Mevociclib
Mevociclib (SY-1365) is a potent and selective covalent CDK7 inhibitor. It has demonstrated anti-tumor activity in preclinical studies, showing efficacy in models of ovarian cancer and acute leukemia, supporting its investigation in both solid and hematological malignancies.
Product Specifications
CAS Number
1816989-16-8
Product Name Alternative
Inhibitor, inhibit, Mevociclib, lung, cancers, cell, CDK, CDK7, CDK7/CycH/MAT1, Cyclin dependent kinase, SY1365, SY-1365, SY 1365, solid, small, TNBC, tumors, triple negative breast cancer
Field of Research
Cell Biology
Purity
98.02% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (6.81 mM) ; DMSO:125 mg/mL (212.91 mM)
Smiles
CN (C) C\C=C\C (=O) Nc1ccc (nc1) C (=O) N[C@@]1 (C) CCC[C@H] (C1) Nc1ncc (Cl) c (n1) -c1c[nH]c2ccccc12
Molecular Formula
C31H35ClN8O2
Molecular Weight
587.11
Storage Conditions
-20°C
Notes
For research use only.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-61686R-BF647-01 20 µL
SMYD3 Recombinant Antibody, AbBy Fluor™ 647 Conjugated
Sign In for Pricing
View Details bsm-61686R-BF647-02 100 µL
SMYD3 Recombinant Antibody, AbBy Fluor™ 647 Conjugated
Sign In for Pricing
View Details